| Literature DB >> 27113409 |
Quanbin Xu1, Dane D Jensen1, Hua Peng2, Yumei Feng3.
Abstract
The systemic renin-angiotensin system (RAS) has long been recognized as a critically important system in blood pressure (BP) regulation. However, extensive evidence has shown that a majority of RAS components are also present in many tissues and play indispensable roles in BP regulation. Here, we review evidence that RAS components, notably including the newly identified (pro)renin receptor (PRR), are present in the brain and are essential for the central regulation of BP. Binding of the PRR to its ligand, prorenin or renin, increases BP and promotes progression of cardiovascular diseases in an angiotensin II-dependent and -independent manner, establishing the PRR a promising antihypertensive drug target. We also review the existing PRR blockers, including handle region peptide and PRO20, and propose a rationale for blocking prorenin/PRR activation as a therapeutic approach that does not affect the actions of the PRR in vacuolar H(+)-ATPase and development. Finally, we summarize categories of currently available antihypertensive drugs and consider future perspectives. Published by Elsevier Inc.Entities:
Keywords: (Pro)renin receptor; (Pro)renin receptor antagonists; Antihypertensive drugs; Brain; Hypertension; Prorenin
Mesh:
Substances:
Year: 2016 PMID: 27113409 PMCID: PMC4942374 DOI: 10.1016/j.pharmthera.2016.04.006
Source DB: PubMed Journal: Pharmacol Ther ISSN: 0163-7258 Impact factor: 12.310